Sargramostim for Myeloid Dendritic Cell Deficiency

Summary

The study will determine whether administration of sargramostim will improve myeloid dendritic cell deficiency in various study groups, including healthy subjects and patients with chronic kidney disease, including those with kidney transplants.

Timeline

Start

2017-02-23

Primary completion

2018-09-17

Completion

2018-09-17

Outcome

Outcome not reported

Stopped: “Insufficient resources necessary for completion.”

Drugs

Indications